atazanavir sulfate has been researched along with Viremia in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Antinori, A; Barbarini, G; Bertoli, A; Bini, T; Caramello, P; Ceccherini-Silberstein, F; Di Perri, G; Gianotti, N; Lorenzini, P; Maserati, R; Melzi, S; Micheli, V; Mussini, C; Narciso, P; Perno, CF; Santoro, MM; Torti, C | 1 |
Bastow, B; Coffin, JM; DiRienzo, AG; Fletcher, CV; Godfrey, C; Maldarelli, F; Margolis, DM; McKinnon, JE; Mellors, JW; Mollan, K; Palmer, S; Swindells, S; Thal, G; Wiegand, A; Wilkin, TJ; Woodward, W | 1 |
Cain, P; Coakley, E; Farthing, C; Gallant, J; Grant, P; Short, W; Taylor, J; Thal, G; Zolopa, A | 1 |
Bhatti, L; Farthing, C; Khanlou, H | 1 |
Antinori, A; Bertoli, A; Caramello, P; Cargnel, A; Carosi, G; Di Perri, G; Esposito, R; Filice, G; Lazzarin, A; Lorenzini, P; Maserati, R; Moroni, M; Narciso, P; Perno, CF; Rizzardini, G; Santoro, MM | 1 |
3 trial(s) available for atazanavir sulfate and Viremia
Article | Year |
---|---|
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; Treatment Outcome; Viremia; Young Adult | 2009 |
Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Viremia; Virus Replication | 2009 |
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Drug Synergism; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Middle Aged; Oligopeptides; Proportional Hazards Models; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Viremia | 2008 |
2 other study(ies) available for atazanavir sulfate and Viremia
Article | Year |
---|---|
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
Topics: Amino Acid Sequence; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Chi-Square Distribution; Codon; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Drug Synergism; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Longitudinal Studies; Male; Multivariate Analysis; Mutation; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2009 |
Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Drug Administration Schedule; Drug Interactions; Furans; HIV Infections; Humans; Oligopeptides; Organophosphates; Pyridines; Sulfonamides; Treatment Failure; Viremia | 2006 |